Search
Now showing items 21-30 of 95
CHD7 and 53BP1 regulate distinct pathways for the re-ligation of DNA double-strand breaks.
(NATURE RESEARCH, 2020-11-13)
Chromatin structure is dynamically reorganized at multiple levels in response to DNA double-strand breaks (DSBs). Yet, how the different steps of chromatin reorganization are coordinated in space and time to differentially ...
Prostate-specific membrane antigen expression in melanoma metastases.
(WILEY, 2020-12-01)
BACKGROUND: Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) ...
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
(BMJ PUBLISHING GROUP, 2020-01-01)
Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient's immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and ...
A high-content RNAi screen reveals multiple roles for long noncoding RNAs in cell division.
(NATURE PUBLISHING GROUP, 2020-04-15)
Genome stability relies on proper coordination of mitosis and cytokinesis, where dynamic microtubules capture and faithfully segregate chromosomes into daughter cells. With a high-content RNAi imaging screen targeting more ...
Changing paradigms in the treatment of residual/recurrent head and neck cancer: implications for dysphagia management.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-01)
PURPOSE OF REVIEW: Despite advances in head and neck cancer treatment provision, recurrence rates remain high with the added risk of successfully treated patients developing a second primary. We report on the management ...
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
(OXFORD UNIV PRESS INC, 2021-02-01)
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard ...
Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers.
(AMER SOC CLINICAL ONCOLOGY, 2020-06-01)
PURPOSE: Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including ...
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
(TAYLOR & FRANCIS LTD, 2020-05-03)
Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model ...
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
(CELL PRESS, 2020-03-27)
Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
(TAYLOR & FRANCIS LTD, 2020-06-02)
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ...